DELTEX MEDICAL GROUP PLC

Regulatory Filings • May 9, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4292N

Deltex Medical Group PLC

09 May 2018

9 May 2018

Deltex Medical Group plc

("Deltex Medical", "Deltex" or the "Company")

TrueVueTM Loops display launched on CardioQ-ODM+ platform

Unique combination of flow and pressure broadens clinical applications

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), today announces the launch of the TrueVueTM Loops display software on its CardioQ-ODM+ haemodynamic monitoring platform.

The TrueVueTM Loops software is being released globally and is initially available in English, US English, French, Spanish, German and Swedish versions. It is available for customers to purchase as a software licence upgrade to their CardioQ-ODM+ monitor platforms.

The TrueVueTM Loops display gives users a simultaneous display of a patient's aortic blood flow velocity and aortic blood pressure. The aortic blood flow velocity is taken directly from the TrueVueTM Doppler probe and the blood pressure from a continuous blood pressure device.

The display has been developed by doctors from Lariboisiere Hospital in Paris. Their research has focused on using TrueVueTM Loops to identify the effects of administering vaso-active drugs and to guide their safe administration. The Company is recruiting other clinical experts to join a collaborarative research effort to look at this and other potential clinical applications.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"Release of the TrueVueTM Loops is an exciting development for the Company. By giving doctors, for the first time ever, a complete and continuous picture of a patient's cenrtral haemodynamic status the Loops should take the science of haemodynamics forward in both intensive and peri-operative care. The initial focus on vaso-active drugs offers the possibility of Deltex building a strong competitive advantage in this area to match its existing strength in fluid management."

For further information, please contact:-

Deltex Medical Group plc	01243 774 837 investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Jonathan Shaw, Group Finance Director
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Chris Hardie Ciaran Walsh
Joint Broker
Turner Pope Investments (TPI) Ltd	0203 621 4120 info@turnerpope.com
Andy Thacker
Financial Public Relations
IFC Advisory Ltd	0203 934 6630
Tim Metcalfe Graham Herring Heather Armstrong

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

Deltex Medical's CardioQ-ODM+ platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

Company goal

Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Company aims to provide clinicians with a single platform, a 'haemodynamic workstation', which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition and skill and expertise of the user. Doing this will enable the Company to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRADGGDULGGBGII